SynthesisJournal of translational medicine2018
Comprehensive and integrative analysis identifies microRNA-106 as a novel non-invasive biomarker for detection of gastric cancer.
Synthesis in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- MicroRNA-486: a dual-function biomarker for diagnosis and tumor immune microenvironment characterization in non-small cell lung cancer.BMC medical genomics · 2025Pooled it
- The clinical implications of circulating microRNAs as potential biomarkers in screening oral squamous cell carcinoma.Frontiers in oncology · 2022Pooled it
- Biomarker Value of miR-221 and miR-222 as Potential Substrates in the Differential Diagnosis of Papillary Thyroid Cancer Based on Data Synthesis and Bioinformatics Approach.Frontiers in endocrinology · 2021Pooled it
- Biomarker roles identification of miR-106 family for predicting the risk and poor survival of colorectal cancer.BMC cancer · 2020Pooled it
- Identification of microRNA-181 as a promising biomarker for predicting the poor survival in colorectal cancer.Cancer medicine · 2019Pooled it
- ncRNAs as Key Regulators in Gastric Cancer: From Molecular Subtyping to Therapeutic Targets.Annals of surgical oncology · 2025Review
- Association of metabolic dysregulation with treatment response in rectal cancer patients undergoing chemoradiotherapy.BMC medical genomics · 2025Article
- The role of dysregulated metabolism and associated genes in gastric cancer initiation and development.Translational cancer research · 2024Review
- In Pursuit of Novel Markers: Unraveling the Potential of miR-106, CEA and CA 19-9 in Gastric Adenocarcinoma Diagnosis and Staging.International journal of molecular sciences · 2024Article
- Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions.Cancer cell international · 2024Review
- Review
- Development of dynamical network biomarkers for regulation in Epstein-Barr virus positive peripheral T cell lymphoma unspecified type.Frontiers in genetics · 2022Article
- Circulating MicroRNAs as Cancer Biomarkers in Liquid Biopsies.Advances in experimental medicine and biology · 2022Review
- Vitamin D modulation and microRNAs in gastric cancer: prognostic and therapeutic role.Translational cancer research · 2021Review
- Diagnostic value and clinical significance of circulating miR-650 and CA211 in detecting of gastric carcinoma.Oncology letters · 2020Article
- MicroRNA in Gastric Cancer Development: Mechanisms and Biomarkers.Diagnostics (Basel, Switzerland) · 2020Review
- Expression and role of nuclear receptor-interacting protein 1 (NRIP1) in stomach adenocarcinoma.Annals of translational medicine · 2020Article
- Prognostic implication and functional exploration for microRNA-20a as a molecular biomarker of gastrointestinal cancer.BMC cancer · 2020Article
- Integrated characterization and validation of the prognostic significance of microRNA-200s in colorectal cancer.Cancer cell international · 2020Article
- Biomarker implication of kallikrein-related peptidases as prognostic tissue substrates of poor survival in colorectal cancer.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, accumulating evidences have revealed that microRNA-106 (miR-106) may serve as a non-invasive and cost-effective biomarker in gastric cancer (GC) detection. However, inconsistent results have prevented its application to clinical practice.
methodsAs a result of this, a comprehensive meta-analysis was conducted to evaluate the diagnostic performance of miR-106 alone and miR-106-related combination markers for GC detection. Meanwhile, an integrative bioinformatics analysis was performed to explore the function of miR-106 at the systems biology level.
resultsThe results in our work showed that sensitivity of 0.71 (95% CI 0.65-0.76) and specificity of 0.82 (0.72-0.88), with the under area AUC (area under the curve) value of 0.80 (0.76-0.83) for miR-106 alone. Prospectively, miR-106-related combination markers improved the combined sensitivity, specificity and AUC, describing the discriminatory ability of 0.78 (0.65-0.87), 0.83 (0.77-0.89) and 0.88 (0.85-0.90) in the present analysis. Furthermore, targets of miR-106 were obtained and enriched by gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis, revealing their associations with the occurrence and development of GC. Hub genes and significant modules were identified from the protein-protein interaction networks constructed by miR-106 targets and found closely associated with the initiation and progression of GC again.
conclusionsOur comprehensive and integrative analysis revealed that miR-106 may be suitable as a diagnostic biomarker for GC while microRNA combination biomarkers may provide a new alternative for clinical application. However, it is necessary to conduct large-scale population-based studies and biological experiments to further investigate the diagnostic value of miR-106.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.